Treatment of herpes simplex virus infections.
Herpes simplex virus infections cause considerable morbidity in immunocompromised and immunocompetent individuals. The development of immunomodulatory agents and nucleoside analog drugs has been responsible for important advances in the treatment of HSV infections. Acyclovir, an acyclic guanosine derivative, has played a major role in the treatment and suppression of HSV episodes in immunocompromised and immunocompetent patients.
D000212:Acyclovir / Q000627:therapeutic use; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007121:Immunocompetence; D007231:Infant, Newborn; D007372:Interferons / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D007372:Interferons; D014740:Vidarabine; D007065:Idoxuridine; D000212:Acyclovir